FY2028 Earnings Forecast for JBIO Issued By HC Wainwright

Key Points

• HC Wainwright analyst A. He forecasts FY2028 EPS of ($2.17 loss per share) for Jade Biosciences and rates the stock a Buy with a $45.00 price target, versus the consensus FY2028 estimate of ($2.21) and FY2029 EPS of ($2.22).
• Shares jumped about 7.5%, opening at $26.85 with a market cap of $1.32 billion and a negative P/E of -5.83; the company beat its last quarter consensus, reporting a ($0.11) EPS versus the ($0.45) expected loss (beat of $0.34).
• The analyst mix is broadly positive—two Strong Buy, five Buy, one Hold and one Sell—giving a MarketBeat consensus rating of Moderate Buy and a consensus price target of $31.17, with several firms recently raising targets (e.g., BTIG to $39, Wedbush $24).

Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 EPS estimates for Jade Biosciences in a report issued on Monday, April 27th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($2.17) per share for the year. HC Wainwright has a "Buy" rating and a $45.00 price objective on the stock. The consensus estimate for Jade Biosciences' current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Jade Biosciences' FY2029 earnings at ($2.22) EPS.

JBIO has been the topic of a number of other research reports. BTIG Research boosted their price objective on shares of Jade Biosciences from $28.00 to $39.00 and gave the company a "buy" rating in a research report on Monday, March 16th. Wedbush restated an "outperform" rating and issued a $24.00 price objective on shares of Jade Biosciences in a research report on Monday, March 9th. Weiss Ratings upgraded shares of Jade Biosciences from a "sell (d-)" rating to a "sell (d)" rating in a research report on Friday. Lifesci Capital upgraded shares of Jade Biosciences to a "strong-buy" rating in a research report on Friday, March 6th. Finally, William Blair upgraded shares of Jade Biosciences to a "strong-buy" rating in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Jade Biosciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.17.

Jade Biosciences Stock Up 7.5%

Jade Biosciences stock opened at $26.85 on Tuesday. The company has a market capitalization of $1.32 billion, a PE ratio of -5.83 and a beta of 1.03. The firm has a fifty day simple moving average of $16.37 and a two-hundred day simple moving average of $14.29. Jade Biosciences has a twelve month low of $6.57 and a twelve month high of $96.95.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last posted its quarterly earnings results on Friday, March 6th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.34.

Hedge Funds Weigh In On Jade Biosciences

Hedge funds have recently modified their holdings of the company. California State Teachers Retirement System lifted its holdings in Jade Biosciences by 40.3% in the fourth quarter. California State Teachers Retirement System now owns 2,850 shares of the company's stock worth $44,000 after buying an additional 819 shares during the period. Russell Investments Group Ltd. lifted its holdings in Jade Biosciences by 40.7% in the third quarter. Russell Investments Group Ltd. now owns 4,422 shares of the company's stock worth $38,000 after buying an additional 1,279 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its holdings in Jade Biosciences by 16.5% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 12,097 shares of the company's stock worth $187,000 after buying an additional 1,709 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Jade Biosciences by 26.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 14,012 shares of the company's stock worth $216,000 after buying an additional 2,940 shares during the period. Finally, Legal & General Group Plc purchased a new stake in Jade Biosciences in the second quarter worth about $29,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.